; (2) if any sums are so invested, and consistent with the legal and fiduciary duties provided under chapter 84 of such title or any other provision of law, divest such sums; and (3) re-invest the divested sums in investments that do not contradict such subparagraph. 18. Protecting pharmaceutical access for Americans (a) List of critical drugs produced exclusively in China (1) In general Not later than 30 days after the date of enactment of this Act, the Commissioner of Food and Drugs shall submit to the Congress a list of all critical drugs and critical active pharmaceutical ingredients— (A) that are produced in China; and (B) the supply of which would be disrupted for United States consumers if such production were discontinued or interrupted. (2) Definitions In this subsection: (A) The term critical active pharmaceutical ingredient means an active pharmaceutical ingredient in a critical drug. (B) The term critical drug means a product that— (i) is a drug (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 )) for which the approval of an application submitted under subsection (b) or (j) of section 505 of such Act ( 21 U.S.C. 355 ) or subsection (a) or (k) of section 351 of the Public Health Service Act ( 42 U.S.C. 352 ) remains in effect